Proposed MHRA changes to UK children's paracetamol dosing recommendations: modelling study

Area of Science:

• Pediatric Pharmacology
• Drug Safety and Regulation
• Evidence-Based Medicine

Background:

• Paracetamol is a common medication for children.
• Concerns exist regarding paracetamol overdose risks with current UK age-based dosing.
• The British National Formulary for Children (BNFC) guidelines have been implicated in potential overdosing.

Purpose of the Study:

• To evaluate the safety of revised UK paracetamol dosing recommendations from the MHRA.
• To compare the proposed MHRA system against existing product dosing instructions.
• To assess the potential for reducing paracetamol overdose in pediatric populations.

Main Methods:

• A theoretical comparison was conducted between the MHRA's proposed dosing system and current UK paracetamol product dosing instructions.
• A previously validated model was used to compare these dosing recommendations.
• Single and cumulative daily paracetamol doses were calculated for various weight centiles (9th, 50th, 91st) across different age groups (3 months, 1, 6, and 12 years).

Main Results:

• Current UK dosing instructions place underweight children at approximately double the recommended paracetamol dose, especially at ages 1 and 6.
• The proposed MHRA dosing system effectively mitigates this risk.
• Underweight, average weight, and overweight children receive doses within or marginally above recommended limits with the MHRA system.

Conclusions:

• The MHRA's proposed paracetamol dosing recommendations enhance child safety by minimizing overdose risks.
• These revised guidelines offer a safer alternative to current product dosing instructions for pediatric paracetamol use.
• The new system demonstrates effectiveness across all pediatric age and weight groups.